Intrexon Corporation (NYSE:XON) SVP Jeffrey Thomas Perez acquired 1,000 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $17.89 per share, for a total transaction of $17,890.00. Following the completion of the acquisition, the senior vice president now owns 12,537 shares of the company’s stock, valued at approximately $224,286.93. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Intrexon Corporation (XON) traded up 5.31% during mid-day trading on Friday, reaching $19.65. The company’s stock had a trading volume of 2,101,114 shares. The company’s 50 day moving average price is $23.08 and its 200-day moving average price is $21.96. Intrexon Corporation has a 1-year low of $17.70 and a 1-year high of $32.90. The company’s market capitalization is $2.35 billion.

Intrexon Corporation (NYSE:XON) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.04% and a negative net margin of 60.63%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.42) earnings per share. Analysts predict that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/jeffrey-thomas-perez-acquires-1000-shares-of-intrexon-corporation-nysexon-stock/1473952.html.

Several large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in Intrexon Corporation by 670.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 83,514 shares of the biotechnology company’s stock worth $2,029,000 after buying an additional 72,675 shares during the period. Norges Bank purchased a new stake in shares of Intrexon Corporation during the fourth quarter valued at approximately $17,300,000. Teachers Advisors LLC boosted its stake in shares of Intrexon Corporation by 6.4% in the fourth quarter. Teachers Advisors LLC now owns 50,172 shares of the biotechnology company’s stock valued at $1,219,000 after buying an additional 3,005 shares during the last quarter. Creative Planning boosted its stake in shares of Intrexon Corporation by 62.1% in the first quarter. Creative Planning now owns 22,308 shares of the biotechnology company’s stock valued at $442,000 after buying an additional 8,547 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Intrexon Corporation by 9,455.4% in the first quarter. CWM LLC now owns 35,546 shares of the biotechnology company’s stock valued at $705,000 after buying an additional 35,174 shares during the last quarter. 84.38% of the stock is currently owned by institutional investors.

XON has been the topic of several research analyst reports. Zacks Investment Research raised Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Tuesday, May 2nd. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the company a “buy” rating in a report on Monday. Finally, BidaskClub raised Intrexon Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Intrexon Corporation presently has an average rating of “Hold” and a consensus price target of $40.50.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.